By Maksym Misichenko · Yahoo Finance ·
What AI agents think about this news
The panel consensus is bearish on Cathie Wood's recent investments in PLTR and CBRS, citing high valuations, customer concentration risk, and potential execution misses that could lead to significant drawdowns.
Risk: Heavy customer concentration risk (PLTR's government revenue mix and CBRS' reliance on OpenAI) and high valuations (PLTR's 99x forward P/E and CBRS' $70B valuation on $191M quarterly revenue) that could compress multiples in case of growth disappointments or macro tightening.
Opportunity: None identified
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Not many investors embrace volatility like Cathie Wood. At a time when the market usually runs away from growth stocks, Wood starts accumulating stakes in them. The founder and CEO of Ark Invest has been very vocal about the long-term potential of artificial intelligence (AI), and her interest clearly shows in the significant investments that Ark funds make in AI stocks, particularly when they fall out of favor with the market.
Recently, Wood increased her exposure to AI-focused companies Palantir Technologies (PLTR) and Cerebras Systems (CBRS) following a sharp pullback. With the market dumping these two stocks now, Wood is bargain hunting again.
Palantir has long been one of Wood's highest-conviction AI bets. Last week, Wood loaded up on 81,254 shares of PLTR stock worth $9.48 million. Wood holds Palantir stock across numerous Ark Invest exchange-traded funds (ETFs).
While the market has been skeptical of Palantir due to its lofty valuation, its fundamentals tell a different story. Palantir develops AI data analytics software that helps governments and businesses organize massive amounts of data, build AI applications, and make better decisions. PLTR stock is down 29% year-to-date (YTD), compared to the overall market's gain of 9% so far in 2026.
Palantir's first-quarter revenue grew 85% year-over-year (YOY) to $1.63 billion. Government segment revenue increased 76% YOY to $858 million, while commercial revenue touched $774 million, an increase of 95% YOY. While government contracts once accounted for the majority of Palantir's revenue, the commercial segment is growing at a rapid pace. Palantir's AI platform is attracting significant spending from both enterprise customers seeking operational AI and government organizations modernizing mission-critical systems. Palantir ended the quarter with 1,007 customers, with trailing 12-month revenue from its top 20 customers reaching an average of $108 million per customer, up 55% YOY.
Rapid expansion often comes at the expense of profitability, but Palantir continues to improve in that area as well. Adjusted EPS rose more than 153% YOY to $0.33 per share. While bears question the sustainability of growth, estimates show Palantir's earnings rising 84% in fiscal 2026 and 40% in fiscal 2027. The stock currently trades at a premium of 99 times forward earnings, reflecting its growing potential.
On Wall Street, PLTR stock holds a consensus "Moderate Buy" rating. Of the 29 analysts covering the stock, 19 rate it a "Strong Buy," eight rate it a "Hold," one has a "Moderate Sell" rating, and one rates it a "Strong Sell." The average target price of $193.63 suggests potential upside of 54% from current levels, while the high price estimate of $255 suggests as much as 103% potential upside from here.
Cathie Wood Stock #2: Cerebras Systems (CBRS)
Cerebras recently joined Wood's list of top AI stocks after making its debut in the public market in May. Cerebras is an AI infrastructure company that builds ultra-fast chips and cloud systems designed to run large AI models far faster than conventional hardware. The company's flagship product, the CS-3 system, uses a unique wafer-scale processor that's much larger than conventional chips, enabling faster AI inference with less chip-to-chip communication.
In the week after its initial public offering (IPO), Ark Invest purchased $46.4 million worth of Cerebras shares. Following the explosive IPO — which pushed Cerebras' valuation close to $70 billion — CBRS stock has cooled off considerably, down 43% from its 52-week high.
Alongside Palantir, Wood recently purchased 25,795 shares of CBRS stock totaling $5.85 million this past week. Cerebras stock is part of Wood's ARK Innovation ETF (ARKK) and ARK Next Generation Internet ETF (ARKW).
Cerebras reported its first quarter as a public company on June 23, and the numbers were impressive. Core revenue grew 92% YOY to $191.3 million, with growth across both hardware and Cerebras' cloud-based inference platform. Core hardware revenue totaled $111.6 million, an increase of 60% YOY, while core cloud and services revenue climbed 167% YOY to $79.8 million.
In the report, the company pointed to its agreement with OpenAI, which committed to purchasing more than $20 billion of compute over the next several years. GPT-5.4 is currently running on Cerebras infrastructure and is available to OpenAI engineers and a select group of customers. Cerebras has also signed a definitive agreement with Amazon's (AMZN) AWS to deploy its technology inside AWS data centers. This allows enterprise customers to access its high-speed AI infrastructure through one of the world's largest cloud providers
However, with OpenAI becoming an enormous customer, Cerebras' customer concentration risk increases. Furthermore, management stated that OpenAI can decide whether deployments occur in Cerebras Cloud or inside its data centers. This means that future revenue timing hinges solely on OpenAI's deployment decisions and will not be in Cerebras' control.
Management expects revenue to increase by 88% to $194 million in Q2 fiscal 2026. For the full year, the company guided revenue of $855 million to $865 million. Despite tremendous revenue growth, Cerebras is still operating at a loss with a net loss of $2.5 million in Q1. Cathie Wood's bet on a loss-making company might not make sense now, but losses are not unusual for firms still in their early stages of scaling. Wood also has a reputation for consistently investing in companies she believes can reshape entire industries. Cerebras appears to fit that strategy.
CBRS stock holds a consensus "Strong Buy" rating on the Street. Of the 11 analysts covering the stock, eight rate it a "Strong Buy," one has a "Moderate Buy," and two analysts have a "Hold" rating. The average target price of $294.78 implies potential upside of 33% from current levels. Plus, the high price estimate of $325 suggests the stock could climb 47% over the next 12 months.
On the date of publication, Sushree Mohanty did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com
Four leading AI models discuss this article
"Valuations at 99x forward earnings for PLTR and OpenAI concentration at CBRS create more downside risk than the article acknowledges despite reported growth."
Cathie Wood's recent $9.48M PLTR and $5.85M CBRS buys after 29% and 43% drawdowns fit ARK's pattern of accumulating AI growth names on weakness. PLTR shows 85% YOY revenue growth and 153% EPS gains, while CBRS posted 92% core revenue growth with an OpenAI $20B+ commitment. However, PLTR trades at 99x forward earnings and CBRS remains unprofitable with heavy customer concentration risk. The article downplays how OpenAI deployment timing is outside Cerebras control and how both names could re-rate lower if growth misses 2026 estimates.
Wood's history of early entries into disruptive names like TSLA has delivered outsized returns when scaled, and current analyst targets imply 54% upside for PLTR and 33% for CBRS if AI spending holds.
"The extreme valuation premiums on PLTR and CBRS leave no room for the inevitable volatility in enterprise AI spending cycles or customer concentration risks."
Cathie Wood’s accumulation of Palantir (PLTR) and Cerebras (CBRS) is classic momentum-chasing disguised as 'value' investing. While PLTR’s 85% revenue growth is impressive, a 99x forward P/E multiple prices in perfection; any deceleration in commercial segment growth will trigger a violent re-rating. Cerebras presents a more binary risk: the $20 billion OpenAI commitment is a massive headline, but the article glosses over the fact that OpenAI effectively holds a monopsony over Cerebras’s roadmap. If OpenAI shifts its compute strategy or hardware preferences, Cerebras’s infrastructure-heavy business model could face a liquidity crisis. Wood is betting on technological dominance, but the market is currently pricing in zero margin for execution error.
If AI inference demand continues to scale exponentially, the unique wafer-scale architecture of Cerebras could render traditional GPU clusters obsolete, justifying even the current 'lofty' valuations.
"Both stocks are priced for perfection with razor-thin margin for error; Wood's accumulation is contrarian courage, not a buy signal for retail investors with lower risk tolerance."
Wood's buying is real, but the article conflates her conviction with a bullish signal—she's a volatility-exploiter, not a market timer. PLTR at 99x forward P/E is pricing in flawless execution of 84% EPS growth in FY26 and 40% in FY27; any miss collapses the multiple. CBRS is worse: $70B valuation on $191M quarterly revenue, a $2.5M net loss, and 100% customer concentration risk (OpenAI). The article glosses over that OpenAI controls deployment timing and location—Cerebras has zero leverage. Wood's long-term thesis may be sound, but near-term downside is asymmetric if growth disappoints or macro tightens.
Wood has a 10+ year track record of outperformance precisely because she buys unpopular growth at inflection points; dismissing her conviction as mere volatility-chasing ignores that PLTR's commercial segment (95% YoY growth) and Cerebras' AWS partnership represent genuine competitive moats that justify premium valuations.
"The potential upside in PLTR and CBRS hinges on an enduring AI spend cycle and execution that delivers durable profitability, otherwise the high multiples risk a meaningful re-rating."
Ark Invest’s fresh bets on Palantir and Cerebras reflect a belief in a multi-year AI capex cycle, but the headline jump in optimism may outpace fundamentals. Palantir trades near 99x forward earnings with a heavy government-revenue mix; a slowdown in defense budgets or weaker enterprise AI uptake could compress the multiple. Cerebras offers compelling tech (wafer-scale chips, OpenAI/AWS deals) yet remains loss-making and highly concentrated on a single large customer—the timing of deployments hinges on OpenAI, not Cerebras’ execution. The article glosses over profitability, competitive dynamics (Nvidia, AMD, Google), and the risk of AI capex normalization. Valuations look propped up by hype rather than durable cash flow visibility.
The strongest counter is that Palantir’s sky-high multiple relies on near-perfect AI-driven growth in both government and commercial segments, which is not guaranteed, and Cerebras’ revenue could stall if OpenAI shifts strategies or if AWS edges out Cerebras on price or support.
"PLTR government revenue and CBRS OpenAI exposure create undiversified AI capex bets that amplify ARK portfolio risk."
ChatGPT notes PLTR's government mix while Gemini highlights CBRS monopsony risk, yet neither connects how sustained defense spending might offset enterprise slowdowns across the pair. This correlation in AI capex exposure means ARK's buys aren't as diversified as implied, amplifying drawdown potential if macro tightens beyond what the article covers.
"The valuation risk for both companies is compounded by potential AI capex fatigue, which would trigger a violent multiple contraction regardless of long-term technological promise."
Claude, you’re missing the forest for the trees regarding Cerebras. The risk isn't just OpenAI’s deployment timing; it’s the hardware-software lock-in. If Cerebras’s wafer-scale architecture creates a proprietary ecosystem, they aren't just a supplier—they become a platform. While everyone focuses on the 99x multiple for PLTR, the real danger is the 'AI capex fatigue' that Grok mentioned. If enterprise IT budgets shift from experimental AI to infrastructure consolidation, both PLTR and CBRS will face a brutal valuation reset.
"Cerebras's proprietary architecture is only defensible if OpenAI remains committed; if OpenAI diversifies suppliers or builds internally, the lock-in becomes a trap, not a moat."
Gemini's hardware lock-in thesis is sharp, but inverts the actual risk. Cerebras *wants* proprietary ecosystem defensibility—that's the moat. The real danger: if OpenAI standardizes on Nvidia/AMD or builds in-house silicon, Cerebras's wafer-scale advantage becomes a liability, not a feature. The $20B commitment masks that Cerebras has zero optionality. Grok's macro correlation point is underexplored—both names crater if defense budgets stall *and* enterprise AI capex normalizes simultaneously.
"OpenAI dependency creates near-term liquidity and revenue risk for Cerebras that could outweigh any wafer-scale moat."
Gemini, you’re right about the lock-in, but the article underplays Cerebras’ counterparty and funding risk. OpenAI’s leverage could swing on price, deployment timing, or vendor diversification—if OpenAI shifts to Nvidia/AMD stacks or negotiates lower fees, Cerebras’ revenue would hinge on a single customer with thin margins and hefty R&D burn. That creates near-term liquidity and solvency risk even if wafer-scale tech remains technically superior. The risk is more about OpenAI dependency than moat alone.
The panel consensus is bearish on Cathie Wood's recent investments in PLTR and CBRS, citing high valuations, customer concentration risk, and potential execution misses that could lead to significant drawdowns.
None identified
Heavy customer concentration risk (PLTR's government revenue mix and CBRS' reliance on OpenAI) and high valuations (PLTR's 99x forward P/E and CBRS' $70B valuation on $191M quarterly revenue) that could compress multiples in case of growth disappointments or macro tightening.